The FDA has approved immunohistochemically assessed cell membrane PD-L1 levels as a predictor of treatment effectiveness; this is used in several cancers such as melanoma, gastrointestinal tumors, non-small cell lung cancer, and EC. The gene discussed is CD274; the disease is cancer.